Abstract
This paper investigated the porcine surfactant protein A (pSP-A) immunogenicity in murine model. Many elegant stu-dies about SP-A therapeutic applications are available however specific studies about its exogenous immunogenicity were not easily assumed. Therefore, we investigated the immunogenicity of this porcine protein in mice. The mice re-ceived pSP-A subcutaneously on days 0 and 7. The animals were observed during 90 days and the blood was collected on days 30, 60 and 90 for assessment the immunogenic potential of pSP-A. Some animals showed circulating antibodies above the screening cut point, which was calculated based on control mice sera signals. However, those antibodies were considered false positive read-outs by the performed competitive inhibition assay. Also no neutralizing antibodies were detected able to avoid the porcine protein ability to promote lipid aggregation. So far in this model, porcine surfactant protein-A could be considered not immunogenic.
Highlights
Alveolar type II cells produce surfactant protein A, SP-A. This protein belongs to a group of soluble humoral pattern recognition receptors, called collectins, which modulate the immune response to microorganisms [1]
The primary unit of a collectin contains an amino-terminal collagen like domain and a carboxyl terminal lectin or carbohydrate recognition domain (CRD) united by a more hydrophobic neck
The assay was standardized using the rabbit polyclonal anti-porcine surfactant protein A (pSP-A) produced with Freund complete adjuvant (FCA) as the positive control diluted 1:2500 versus different pSP-A concentrations to built a calibration curve to establish the necessary amount of pSP-A to assure the specific inhibition or the specificity cut point
Summary
Alveolar type II cells produce surfactant protein A, SP-A This protein belongs to a group of soluble humoral pattern recognition receptors, called collectins, which modulate the immune response to microorganisms [1]. Regulatory discussions about immunogenicity of therapeutic proteins represent today a central issue of biopharmaceuticals both by developers and by regulators cause an unwanted immunogenicity may lead to a loss of product efficacy besides severe side effects. These effects could develop more deleterious consequences to the patient (allergy, anaphylaxis, serum sickness, neutralization of the drug or native protein) [6,7].
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
